1Elevan Bio Scales Domestic Peptide Manufacturing Amid Regulatory Shift

The July 23–24 meeting of the FDA advisory committee brought clarity to the industry, with members recommending six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—for the affirmative bulk drug substances list. While these recommendations are non-binding and await formal rulemaking, they provide a roadmap for companies like 1Elevan Bio to professionalize a sector often characterized by fragmented operations.

CEO Darrin Carrico argues that the current market lacks a unified approach to safety and data. By integrating domestic manufacturing with pharmacy dispensing and real-world outcomes monitoring, the company intends to move beyond the "single-point" business models common among telehealth and compounding providers. The goal is to establish a rigorous, transparent supply chain that can withstand increased federal scrutiny. Even as the regulatory process continues, 1Elevan Bio is positioning its Fisher-based operations to serve as a primary resource for providers seeking verified, legally compounded therapeutics.